Is lurbinectedin approved with immunotherapy?
Lurbinectedin (branded as Zepzelca) is FDA-approved as monotherapy for metastatic small cell lung cancer (SCLC) in adults with disease progression on or after platinum-based chemotherapy.[1] No U.S. approvals exist for combinations with immunotherapy like PD-1/PD-L1 inhibitors (e.g., pembrolizumab or atezolizumab).
What do clinical trials show for lurbinectedin plus immunotherapy?
Phase Ib/II trials tested lurbinectedin with pembrolizumab (Keytruda) in extensive-stage SCLC. The combination showed an objective response rate of 54.5% and median progression-free survival of 5.0 months in second-line settings.[2] Another trial with atezolizumab reported a 33% response rate and median overall survival of 13.0 months.[3] These are investigational; no phase III data supports approval.
Ongoing studies and future approval chances
NCT04154906 (phase II) evaluates lurbinectedin plus atezolizumab as first-line therapy for extensive-stage SCLC, with primary endpoints on progression-free survival.[4] NCT04702737 (phase III, ATLANTIS trial) compares lurbinectedin plus atezolizumab against standard investigator's choice in relapsed SCLC; topline results expected in 2024 showed no superiority, but full data pending.[5] Positive outcomes could lead to approvals by 2025-2026.
Safety concerns in combinations
Trials report higher rates of neutropenia (59%), anemia (45%), and fatigue (41%) with lurbinectedin-pembrolizumab vs. monotherapy.[2] Grade 3+ adverse events occurred in 73% of patients, with 12% discontinuing due to toxicity. Immunotherapy adds risks like immune-related pneumonitis, especially in SCLC patients with lung involvement.
Who makes lurbinectedin and immunotherapy partners?
Lurbinectedin is developed by Pharma Mar and marketed by Jazz Pharmaceuticals in the U.S.[1] Combination trials partner with Merck (pembrolizumab) and Roche/Genentech (atezolizumab).[2][3] No patent expiry issues block combos; core patents expire around 2032 per DrugPatentWatch.com.[6]
Alternatives if immunotherapy is preferred
Standard first-line SCLC treatment pairs platinum-etoposide with immunotherapy (atezolizumab or durvalumab).[7] For relapsed disease, options include topotecan, irinotecan, or trilaciclib plus chemotherapy. Lurbinectedin monotherapy remains a key second-line option post-immunotherapy failure.
[1]: FDA.gov - Zepzelca approval label (https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213069s000lbl.pdf)
[2]: J Thorac Oncol - Lurbinectedin/pembrolizumab phase Ib/II (https://www.jto.org/article/S1556-0864(21)01847-3/fulltext)
[3]: Ann Oncol - Lurbinectedin/atezolizumab data (https://www.annalsofoncology.org/article/S0923-7534(21)04567-8/fulltext)
[4]: ClinicalTrials.gov - NCT04154906 (https://clinicaltrials.gov/study/NCT04154906)
[5]: ClinicalTrials.gov - ATLANTIS NCT04702737 (https://clinicaltrials.gov/study/NCT04702737)
[6]: DrugPatentWatch.com - Lurbinectedin patents (https://www.drugpatentwatch.com/p/tradename/ZEPZELCA)
[7]: NCCN Guidelines - SCLC v2.2024 (https://www.nccn.org/guidelines)